Health related quality of life findings from COMBI-AD

Source: eCancer, June 2018

Dr Schadendorf speaks with ecancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago about patient perspectives and QOL feedback following adjuvant treatment with dabrafenib and trametinib to treat resected stage III BRAF melanoma.

Dr Schadendorf notes that during treatment in the COMBI-AD trial, which ecancer reported on here, up to a quarter of patients discontinued treatment due to toxicity.

Ultimately those that remained in the trial saw their quality of life improve, and he considers how better communication of expectations in treatment tolerability may boost trial retention, and ultimately survival.